13125 Berlin, de
+49 (30) 941084-138
Eckert & Ziegler acquires the Analytic Instrumentation and Radiochemistry Equipment Business from American market leader Bioscan, Inc.
Eckert & Ziegler Radiopharma Board member, Dr. André Heß, explained: "The products we have acquired ideally enhance our developing equipment business and ensure we can offer our customers system solutions for the production and quality assurance of radiopharmaceuticals. By such an investment we are broadening our commitment to the North American market."
"Bioscan has been a leading player in radioanalytic and radiochemistry instrumentation for more than thirty years. Over the past five years, the company has increasingly focused on its fast-growing molecular imaging business", commented Alex Kleinman, Vice President of Marketing and Business Development for Bioscan. "Today's transaction will enable Bioscan to increase investment in its rapidly expanding preclinical imaging product line. We are pleased to be able to entrust our radiopharmaceutical equipment business and the thousands of customers that use Bioscan radioanalytic and radiochemistry instruments every day to a market leader like Eckert & Ziegler."
Radiopharmaceuticals are used in so-called positron emission tomography (PET) to ensure swift and accurate identification of cancerous tissue and neurodegenerative disease. A large number of radiopharmaceuticals are currently in the development pipeline and consequently the associated equipment market continues to grow. In addition to its radiopharmaceutical synthesis equipment business, Eckert & Ziegler has several Fluorine-18 PET radiopharmaceutical production locations in Germany and also supplies research institutes worldwide with its Gallium-68 (PET) radio nuclide generators for nuclear imaging. In addition to these radio-diagnostic products Eckert & Ziegler also markets the EMEA approved product Yttriga, an Yttrium-90 precursor for numerous radiotherapeutic products.
Bioscan is a leading supplier of preclinical nano-tomographic molecular imaging systems that enable breakthroughs in the discovery, validation and development of novel therapeutics. Preclinical imaging uses molecular biomarkers in animals to conduct in vivo studies that generate more relevant and consistent biological data while reducing research cost and complexity. The company's cutting-edge SPECT, PET, Optical and X-Ray CT imaging tools are used by more than 100 academic institutions, government research organizations, pharmaceutical and biotechnology companies to improve their disease, drug discovery and development research. The unique imaging acuity enabled by Bioscan's patented technologies makes it possible to translate research protocols and results directly from small animal models of human diseases to human clinical trials, driving increased speed to market for drugs. For more information about Bioscan please visit www.bioscan.com.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.